Cost-effectiveness of vildagliptin for people with type 2 diabetes mellitus in Brazil: findings and implications

Gustavo Laine Araujo de Oliveira, Augusto Afonso Guerra Júnior, Brian Godman, Francisco de Assis Acúrcio

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Introduction: Vildagliptin is an inhibitor of the enzyme dipeptidyl peptidase 4, indicated for the treatment of type 2 diabetes mellitus, combined or not with metformin. This study aims to evaluate the cost-effectiveness of vildagliptin in the Brazilian context. Areas covered: Using MEDLINE, Cochrane Library, Lilacs and CRD, six studies were selected for the economic models. This study utilised cost data in the Brazilian health system to provide the context.
Expert commentary: Type 2 diabetes mellitus is an epidemic disease and represents a challenge for all health care systems. Although guidelines clearly define first-line treatment, there are several other promising treatments. Vildagliptin is one of them, resulting in a mean lifetime increase of 0.31 years compared to metformin alone and 1.19 more life years compared to other metformin combinations. Considering observational data, life years with dual vildagliptin-containing treatments were 0.37 more compared to other dual treatments. However, its high cost versus generic metformin and its unclear safety profile weakens its subsequent cost-effectiveness. Consequently, the incorporation of vildagliptin or its combination with metformin is currently not recommended for the Brazilian Health Care System. This may change as more data becomes available.
LanguageEnglish
Pages109-119
Number of pages11
JournalExpert Review of Pharmacoeconomics and Outcomes Research
Volume17
Issue number2
Early online date9 Feb 2017
DOIs
Publication statusPublished - 22 Feb 2017

Fingerprint

Metformin
Type 2 Diabetes Mellitus
Cost-Benefit Analysis
Brazil
Dipeptidyl-Peptidase IV Inhibitors
Economic Models
Delivery of Health Care
Costs and Cost Analysis
MEDLINE
Libraries
vildagliptin
Guidelines
Safety
Health

Keywords

  • vildagliptin
  • cost-effectiveness
  • Brazil
  • type 2 diabetes
  • metformin

Cite this

de Oliveira, Gustavo Laine Araujo ; Guerra Júnior, Augusto Afonso ; Godman, Brian ; de Assis Acúrcio, Francisco. / Cost-effectiveness of vildagliptin for people with type 2 diabetes mellitus in Brazil : findings and implications. In: Expert Review of Pharmacoeconomics and Outcomes Research. 2017 ; Vol. 17, No. 2. pp. 109-119.
@article{2db10275add446859176021723082675,
title = "Cost-effectiveness of vildagliptin for people with type 2 diabetes mellitus in Brazil: findings and implications",
abstract = "Introduction: Vildagliptin is an inhibitor of the enzyme dipeptidyl peptidase 4, indicated for the treatment of type 2 diabetes mellitus, combined or not with metformin. This study aims to evaluate the cost-effectiveness of vildagliptin in the Brazilian context. Areas covered: Using MEDLINE, Cochrane Library, Lilacs and CRD, six studies were selected for the economic models. This study utilised cost data in the Brazilian health system to provide the context.Expert commentary: Type 2 diabetes mellitus is an epidemic disease and represents a challenge for all health care systems. Although guidelines clearly define first-line treatment, there are several other promising treatments. Vildagliptin is one of them, resulting in a mean lifetime increase of 0.31 years compared to metformin alone and 1.19 more life years compared to other metformin combinations. Considering observational data, life years with dual vildagliptin-containing treatments were 0.37 more compared to other dual treatments. However, its high cost versus generic metformin and its unclear safety profile weakens its subsequent cost-effectiveness. Consequently, the incorporation of vildagliptin or its combination with metformin is currently not recommended for the Brazilian Health Care System. This may change as more data becomes available.",
keywords = "vildagliptin, cost-effectiveness, Brazil, type 2 diabetes, metformin",
author = "{de Oliveira}, {Gustavo Laine Araujo} and {Guerra J{\'u}nior}, {Augusto Afonso} and Brian Godman and {de Assis Ac{\'u}rcio}, Francisco",
year = "2017",
month = "2",
day = "22",
doi = "10.1080/14737167.2017.1292852",
language = "English",
volume = "17",
pages = "109--119",
journal = "Expert Review of Pharmacoeconomics and Outcomes Research",
issn = "1473-7167",
number = "2",

}

Cost-effectiveness of vildagliptin for people with type 2 diabetes mellitus in Brazil : findings and implications. / de Oliveira, Gustavo Laine Araujo; Guerra Júnior, Augusto Afonso; Godman, Brian; de Assis Acúrcio, Francisco.

In: Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 17, No. 2, 22.02.2017, p. 109-119.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Cost-effectiveness of vildagliptin for people with type 2 diabetes mellitus in Brazil

T2 - Expert Review of Pharmacoeconomics and Outcomes Research

AU - de Oliveira, Gustavo Laine Araujo

AU - Guerra Júnior, Augusto Afonso

AU - Godman, Brian

AU - de Assis Acúrcio, Francisco

PY - 2017/2/22

Y1 - 2017/2/22

N2 - Introduction: Vildagliptin is an inhibitor of the enzyme dipeptidyl peptidase 4, indicated for the treatment of type 2 diabetes mellitus, combined or not with metformin. This study aims to evaluate the cost-effectiveness of vildagliptin in the Brazilian context. Areas covered: Using MEDLINE, Cochrane Library, Lilacs and CRD, six studies were selected for the economic models. This study utilised cost data in the Brazilian health system to provide the context.Expert commentary: Type 2 diabetes mellitus is an epidemic disease and represents a challenge for all health care systems. Although guidelines clearly define first-line treatment, there are several other promising treatments. Vildagliptin is one of them, resulting in a mean lifetime increase of 0.31 years compared to metformin alone and 1.19 more life years compared to other metformin combinations. Considering observational data, life years with dual vildagliptin-containing treatments were 0.37 more compared to other dual treatments. However, its high cost versus generic metformin and its unclear safety profile weakens its subsequent cost-effectiveness. Consequently, the incorporation of vildagliptin or its combination with metformin is currently not recommended for the Brazilian Health Care System. This may change as more data becomes available.

AB - Introduction: Vildagliptin is an inhibitor of the enzyme dipeptidyl peptidase 4, indicated for the treatment of type 2 diabetes mellitus, combined or not with metformin. This study aims to evaluate the cost-effectiveness of vildagliptin in the Brazilian context. Areas covered: Using MEDLINE, Cochrane Library, Lilacs and CRD, six studies were selected for the economic models. This study utilised cost data in the Brazilian health system to provide the context.Expert commentary: Type 2 diabetes mellitus is an epidemic disease and represents a challenge for all health care systems. Although guidelines clearly define first-line treatment, there are several other promising treatments. Vildagliptin is one of them, resulting in a mean lifetime increase of 0.31 years compared to metformin alone and 1.19 more life years compared to other metformin combinations. Considering observational data, life years with dual vildagliptin-containing treatments were 0.37 more compared to other dual treatments. However, its high cost versus generic metformin and its unclear safety profile weakens its subsequent cost-effectiveness. Consequently, the incorporation of vildagliptin or its combination with metformin is currently not recommended for the Brazilian Health Care System. This may change as more data becomes available.

KW - vildagliptin

KW - cost-effectiveness

KW - Brazil

KW - type 2 diabetes

KW - metformin

UR - http://www.tandfonline.com/doi/abs/10.1080/14737167.2017.1292852

U2 - 10.1080/14737167.2017.1292852

DO - 10.1080/14737167.2017.1292852

M3 - Article

VL - 17

SP - 109

EP - 119

JO - Expert Review of Pharmacoeconomics and Outcomes Research

JF - Expert Review of Pharmacoeconomics and Outcomes Research

SN - 1473-7167

IS - 2

ER -